PIVKA-II is a useful marker in patients with modified UICC T3 stage hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1456-1462

  Kim, Jong Man ^a   Kwon, Choon Hyuck David ^a   Joh, Jae Won ^a   Park, Jae Berm ^a   Lee, Joon Hyeok ^a   Kim, Sung Joo ^a   Paik, Seung Woon ^a   Park, Cheol Keun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Liver resection; Modified uicc staging; PIVKA II; Tumor recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; DECARBOXYPROTHROMBIN; HEMOGLOBIN; PROTEIN; SERUM ALBUMIN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOTTING; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTE COUNT; TUMOR INVASION; UNION FOR INTERNATIONAL CANCER CONTROL STAGING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885725653     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge13058     Document Type: Article

References (20)

1. Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16. (Pubitemid 39423365)
2. Park JW: [Hepatocellular carcinoma in Korea: introduction and overview]. Korean J Gastroenterol 2005; 45:217-226.
3. Park JW: [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol 2004; 10:88-98.
4. Bruix J, Sherman M, Llovet JM, et al.: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430. (Pubitemid 32844200)
5. Greten TF, Papendorf F, Bleck JS, et al.: Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92:1862-1868. (Pubitemid 40826134)
6. El-Serag HB, Siegel AB, Davila JA, et al.: Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44:158-166. (Pubitemid 41772530)
7. Edmondson HA, Steiner PE: Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7:462-503.
8. Ueno S, Tanabe G, Nuruki K, et al.: Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002; 24:395-403. (Pubitemid 36002129)
9. Sala M, Forner A, Varela M, Bruix J: Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005; 25:171-180. (Pubitemid 40781070)
10. Yamamoto K, Imamura H, Matsuyama Y, et al.: Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol 2009; 16:2795-2804.
11. Okuwaki Y, Nakazawa T, Shibuya A, et al.: Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol 2008; 43:71-78. (Pubitemid 351324989)
12. Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M: Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42:962-968.
13. Tang W, Miki K, Kokudo N, et al.: Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22:969-975.
14. Imamura H, Matsuyama Y, Miyagawa Y, et al.: Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999; 86:1032-1038. (Pubitemid 29387069)
15. Koike Y, Shiratori Y, Sato S, et al.: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91:561-569.
16. Khan KN, Yatsuhashi H, Yamasaki K, et al.: Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32:269-278. (Pubitemid 30093906)
17. Nagaoka S, Yatsuhashi H, Hamada H, et al.: The des-gammacarboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003; 98:2671-2677. (Pubitemid 37509532)
18. Suehiro T, Matsumata T, ltasaka H, Taketomi A, Yamamoto K, Sugimachi K: Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma. Surgery 1995; 117:682-691.
19. Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36:161-170.
20. Ueshima K, Kudo M, Takita M, et al.: Des-gamma-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011; 29:321-325.